semaglutide – Medxy AI

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY 10/31/2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, adverse events, cardiovascular outcomes, and evidence certainty.

Diabetes & Endocrinology Psychiatry Specialties

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY 10/22/2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychiatric symptoms.

Diabetes & Endocrinology Specialties

Enhanced Weight Reduction with Once-Weekly Semaglutide 7.2 mg in Obesity Management: Insights from the STEP UP Phase 3b Trial

By MedXY 10/18/2025

The STEP UP trial demonstrates that once-weekly semaglutide 7.2 mg significantly improves weight loss outcomes versus 2.4 mg and placebo in adults with obesity, with a manageable safety profile.

Diabetes & Endocrinology Gastroenterology news

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 10/09/2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Clinical Updates news OB/GYN & Women's Health Specialties

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

By MedXY 09/16/2025

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Diabetes & Endocrinology Specialties

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY 09/07/2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerability.

Diabetes & Endocrinology Specialties

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY 09/07/2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Clinical Updates Diabetes & Endocrinology news Specialties

Consistent Improvement in Walking Function Across Diabetes Profiles with Semaglutide in Peripheral Artery Disease: Lessons from the STRIDE Trial

By MedXY 09/07/2025

The STRIDE trial demonstrates that once-weekly semaglutide significantly enhances walking capacity in patients with symptomatic peripheral artery disease and type 2 diabetes, irrespective of baseline diabetes duration, BMI, HbA1c levels, or diabetes medication use.

Cardiology Clinical Updates news Specialties

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

By MedXY 08/31/2025

Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.

Diabetes & Endocrinology Specialties

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY 08/28/2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option for obesity management.

Cardiology Diabetes & Endocrinology Nephrology Specialties

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Clinical Updates Diabetes & Endocrinology news Specialties

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY 08/05/2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Diabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

Diabetes & Endocrinology news Specialties

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

By MedXY 07/28/2025

Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.

news

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

By MedXY 07/28/2025

Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.

Diabetes & Endocrinology news

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.